| Title |
Partial breast irradiation with CyberKnife after breast conserving surgery: a pilot study in early breast cancer
|
|---|---|
| Published in |
Radiation Oncology, March 2018
|
| DOI | 10.1186/s13014-018-0991-4 |
| Pubmed ID | |
| Authors |
Laura Lozza, Laura Fariselli, Marco Sandri, Mario Rampa, Valentina Pinzi, Maria Carmen De Santis, Marzia Franceschini, Giovanna Trecate, Ilaria Maugeri, Luisa Fumagalli, Francesca Bonfantini, Giulia Bianchi, Emanuele Pignoli, Elena De Martin, Roberto Agresti |
| Abstract |
Local recurrences after breast conserving treatment are mainly close to the original tumor site, and as such shorter fractionation strategies focused on and nearest mammary gland, i.e. accelerated partial breast irradiation (APBI), have been developed. Stereotactic APBI has been attempted, although there is little experience using CyberKnife (CK) for early breast cancer. This pilot study was designed to assess the feasibility of CK-APBI on 20 evaluable patients of 29 eligible, followed for 2 years. The primary endpoint was acute/sub-acute toxicity; secondary endpoints were late toxicity and the cosmetic result. Mean pathological tumor size was 10.5 mm (±4.3, range 3-18), 8 of these patients were classified as LumA-like, 11 as LumB-like, and 1 as LumB-HER2-enriched. Using CK-APBI with Iris, the treatment time was approximately 60 min (range~ 35 to ~ 120). All patients received 30 Gy in five fractions delivered to the PTV. The median number of beams was 180 (IQR 107-213; range:56-325) with a median PTV isodose prescription of 86.0% (IQR 85.0-88.5; range:82-94). The median PTV was 88.1 cm3 (IQR 63.8-108.6; range:32.3-238.8). The median breast V100 and V50 was 0.6 (IQR 0.1-1.5; range:0-13) and 18.6 (IQR 13.1-21.7; range:7.5-37), respectively. The median PTV minimum dose was 26.2 Gy (IQR 24.7-27.6; range 22.3-29.3). Mild side effects were recorded during the period of observation. Cosmetic evaluations were performed by three observers from the start of radiotherapy up to 2 years. Patients' evaluation progressively increase from 60% to 85% of excellent rating; this trend was similar to that of external observer. These preliminary results showed the safe feasibility of CK-APBI in early breast cancer, with mild acute and late toxicity and very good cosmetic results. The present study is registered at Clinicaltrial.gov ( NCT02896322 ). Retrospectively egistered August 4, 2016. |
X Demographics
The data shown below were collected from the profiles of 3 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Switzerland | 1 | 33% |
| Unknown | 2 | 67% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 2 | 67% |
| Scientists | 1 | 33% |
Mendeley readers
The data shown below were compiled from readership statistics for 46 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 46 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 9 | 20% |
| Other | 4 | 9% |
| Student > Bachelor | 3 | 7% |
| Librarian | 2 | 4% |
| Professor | 2 | 4% |
| Other | 9 | 20% |
| Unknown | 17 | 37% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 15 | 33% |
| Nursing and Health Professions | 4 | 9% |
| Physics and Astronomy | 3 | 7% |
| Biochemistry, Genetics and Molecular Biology | 2 | 4% |
| Mathematics | 1 | 2% |
| Other | 3 | 7% |
| Unknown | 18 | 39% |
Attention Score in Context
This research output has an Altmetric Attention Score of 2. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 28 October 2020.
All research outputs
#14,527,988
of 23,267,128 outputs
Outputs from Radiation Oncology
#822
of 2,090 outputs
Outputs of similar age
#189,167
of 332,140 outputs
Outputs of similar age from Radiation Oncology
#22
of 49 outputs
Altmetric has tracked 23,267,128 research outputs across all sources so far. This one is in the 35th percentile – i.e., 35% of other outputs scored the same or lower than it.
So far Altmetric has tracked 2,090 research outputs from this source. They receive a mean Attention Score of 2.8. This one has gotten more attention than average, scoring higher than 56% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 332,140 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 40th percentile – i.e., 40% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 49 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 57% of its contemporaries.